BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 19638274)

  • 1. The effects of exosite occupancy on the substrate specificity of thrombin.
    Ng NM; Quinsey NS; Matthews AY; Kaiserman D; Wijeyewickrema LC; Bird PI; Thompson PE; Pike RN
    Arch Biochem Biophys; 2009 Sep; 489(1-2):48-54. PubMed ID: 19638274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II.
    Monteiro RQ; Rapôso JG; Wisner A; Guimarães JA; Bon C; Zingali RB
    Biochem Biophys Res Commun; 1999 Sep; 262(3):819-22. PubMed ID: 10471408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Energetics of thrombin-thrombomodulin interaction.
    Vindigni A; White CE; Komives EA; Di Cera E
    Biochemistry; 1997 Jun; 36(22):6674-81. PubMed ID: 9184147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin specificity.
    Guillin MC; Bezeaud A; Bouton MC; Jandrot-Perrus M
    Thromb Haemost; 1995 Jul; 74(1):129-33. PubMed ID: 8578445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to thrombin directed against both of its cryptic exosites.
    Mollica L; Preston RJ; Chion AC; Lees SJ; Collins P; Lewis S; Lane DA
    Br J Haematol; 2006 Feb; 132(4):487-93. PubMed ID: 16412021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex.
    Chen K; Stafford AR; Wu C; Yeh CH; Kim PY; Fredenburgh JC; Weitz JI
    Biochemistry; 2017 Jun; 56(24):3119-3128. PubMed ID: 28549218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity.
    Ye J; Liu LW; Esmon CT; Johnson AE
    J Biol Chem; 1992 Jun; 267(16):11023-8. PubMed ID: 1317850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex.
    Fuentes-Prior P; Iwanaga Y; Huber R; Pagila R; Rumennik G; Seto M; Morser J; Light DR; Bode W
    Nature; 2000 Mar; 404(6777):518-25. PubMed ID: 10761923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fluid phase and clot-bound thrombin by the thrombin exosite I ligand LU 58463: comparison with heparin and hirudin.
    Filippucci E; Agnelli G; Leone M; Nenci GG
    Haematologica; 2002 Oct; 87(10):1116-7. PubMed ID: 12368171
    [No Abstract]   [Full Text] [Related]  

  • 10. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.
    Vijayalakshmi J; Padmanabhan KP; Mann KG; Tulinsky A
    Protein Sci; 1994 Dec; 3(12):2254-71. PubMed ID: 7756983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II.
    Verhamme IM; Olson ST; Tollefsen DM; Bock PE
    J Biol Chem; 2002 Mar; 277(9):6788-98. PubMed ID: 11724802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
    Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
    Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the substrate-binding exosites of two snake venom serine proteinases: molecular basis for the partition of two essential functions of thrombin.
    Maroun RC; Serrano SM
    J Mol Recognit; 2004; 17(1):51-61. PubMed ID: 14872537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin.
    Arocas V; Lemaire C; Bouton MC; Bezeaud A; Bon C; Guillin MC; Jandrot-Perrus M
    Thromb Haemost; 1998 Jun; 79(6):1157-61. PubMed ID: 9657441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of exosites 1 and 2 in thrombin reaction with plasminogen activator inhibitor-1 in the absence and presence of cofactors.
    Rezaie AR
    Biochemistry; 1999 Nov; 38(44):14592-9. PubMed ID: 10545182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes.
    Tasset DM; Kubik MF; Steiner W
    J Mol Biol; 1997 Oct; 272(5):688-98. PubMed ID: 9368651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
    Su Z; Vinogradova A; Koutychenko A; Tolkatchev D; Ni F
    Protein Eng Des Sel; 2004 Aug; 17(8):647-57. PubMed ID: 15358856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics.
    Jabaiah AM; Getz JA; Witkowski WA; Hardy JA; Daugherty PS
    Biol Chem; 2012 Sep; 393(9):933-41. PubMed ID: 22944693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosites determine macromolecular substrate recognition by prothrombinase.
    Krishnaswamy S; Betz A
    Biochemistry; 1997 Oct; 36(40):12080-6. PubMed ID: 9315846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occupancy of anion binding exosite 2 on thrombin determines Ca2+ dependence of protein C activation.
    Liu LW; Rezaie AR; Carson CW; Esmon NL; Esmon CT
    J Biol Chem; 1994 Apr; 269(16):11807-12. PubMed ID: 8163479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.